EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants

Jian Yue, Courtney E LeSon, Casey A Rimland, Kailey Brodeur, Rachel Weng, Evan E Hsu, Michael T Lam iD, Manpreet Meyer iD, Seigo Okada, Andrew L D Hsu, Musaab A Alhezam, Megan M Perron und 44 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Jian Yue und 55 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Adenosine Deaminase, Intercellular Signaling Peptides and Proteins, Polyarteritis Nodosa, Severe Combined Immunodeficiency. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIDDK NIH HHS, Rheumatology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2 activity.

Methods

Data were collected from individuals who underwent ADA2 testing from 2018 to 2025. Plasma ADA2 activity was determined using an established spectrophotometric assay. ADA2 variants were analyzed in transfected cells by enzyme assay and western blotting.

Results

We determined that plasma ADA2 activity is 99.0% and 96.0% sensitive and 99.7% and 98.8% specific in distinguishing genetically confirmed DADA2 cases from controls and carriers, respectively. Eighteen individuals with DADA2 (9%) possessed detectable ADA2 activity, including several cases with levels seen in carriers. Residual ADA2 activity was associated with the vasculitis/inflammatory phenotype but not with disease severity. Genotype analysis revealed that 14 of 18 cases with residual plasma activity possessed at least one hypomorphic missense variant with greater than 20% residual ADA2 function when overexpressed in 293T cells, often occurring in trans with a more deleterious variant. In vitro analysis revealed that missense ADA2 variants exert variable dominant‐negative effects by forming large intracellular protein aggregates via disulfide bond formation at a cysteine residue (Cys408).

Conclusion

We confirmed the utility of plasma ADA2 activity as a diagnostic assay and showed that the inflammatory phenotype of DADA2 occurred in cases with residual activity. In vitro findings illustrate potential interactions of ADA2 variants to synergistically disrupt protein function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine DeaminaseIntercellular Signaling Peptides and ProteinsPolyarteritis NodosaSevere Combined ImmunodeficiencyHumansFemaleMaleAdultMiddle AgedMutation, MissenseSensitivity and SpecificityAgammaglobulinemia

Substanzen

Adenosine DeaminaseADA2 protein, humanIntercellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China.
  • Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Medical Scientist Training Program, UMass Chan Medical School, Worcester, Massachusetts.
  • Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts.

ORCID-Profile: Michael T Lam, Manpreet Meyer, Fatma Dedeoglu, Peter A Nigrovic, Katherine D Nowicki, Leonardo Oliveira Mendonca, Taha Moussa, Archana Khan, Chengappa Kavadichanda, Aman Sharma, Pui Y Lee

Förderung

  • NIAID NIH HHS
  • NIDDK NIH HHS
  • Rheumatology Research Foundation

Zitieren

APA

Yue, J., LeSon, C. E., Rimland, C. A., Brodeur, K., Weng, R., Hsu, E. E., Lam, M. T., Meyer, M., Okada, S., Hsu, A. L. D., Alhezam, M. A., Perron, M. M., Halyabar, O., Dedeoglu, F., Nigrovic, P. A., Shimamura, A., Rowe, R. G., Cooper, M. A., Vogel, T. P., …, & Lee, P. Y. (2025). Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants. Arthritis & Rheumatology. https://doi.org/10.1002/art.43412

Vancouver

Yue J, LeSon CE, Rimland CA, Brodeur K, Weng R, Hsu EE, et al. Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants. Arthritis & Rheumatology. 2025. doi:10.1002/art.43412

BibTeX
@article{Yue2025,
  author = {Yue, Jian and LeSon, Courtney E and Rimland, Casey A and Brodeur, Kailey and Weng, Rachel and Hsu, Evan E and Lam, Michael T and Meyer, Manpreet and Okada, Seigo and Hsu, Andrew L D and Alhezam, Musaab A and Perron, Megan M and Halyabar, Olha and Dedeoglu, Fatma and Nigrovic, Peter A and Shimamura, Akiko and Rowe, R Grant and Cooper, Megan A and Vogel, Tiphanie P and Gillispie-Taylor, Miriah and Peterson, Rosemary and Lin, Clara and Nowicki, Katherine D and Dollerschell, Kaylee and Nakano, Taizo A and Labrosse, Roxane and Cochino, Alexis-Virgil and Ioan, Andreea and Mendonca, Leonardo Oliveira and Barros, Samar Freschi and Kalil, Jorge and Perez-Rojas, Javier and Diaz-Kuan, Alicia and Sobel, Eric S and Moussa, Taha and Lee, Samuel Shang Ming and Koh, Li Wearn and Khan, Archana and Sutnga, Sodality and Khubchandani, Raju and Shoman, Walaa and El Chazli, Yasmine and Pinto, Benzeeta and Kavadichanda, Chengappa and Abraham, Roshini S and Sun, Xiangwei and Zhou, Qing and Naidu, Gsrsnk and Sharma, Aman and Esperanzate, Carl and Kastner, Daniel L and Aksentijevich, Ivona and Kelly, Susan J and Hershfield, Michael and Tarrant, Teresa K and Lee, Pui Y},
  title = {Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43412}
}
Kostenlos starten →